Polo-like 激酶在非小细胞肺癌中的表达分析及其预后价值。
Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
机构信息
Department of Respiration, The Second Affiliated Hospital of Guangdong Medical University, 12# Minyou Road, Xiashan, Zhanjiang, 524003, Guangdong, People's Republic of China.
Graduate School, Guangdong Medical University, 2# Wenming Eastern Road, Xiashan, Zhanjiang, 524023, Guangdong, People's Republic of China.
出版信息
J Cancer Res Clin Oncol. 2020 Oct;146(10):2447-2460. doi: 10.1007/s00432-020-03288-6. Epub 2020 Jul 5.
BACKGROUND
Despite great advances in its early diagnosis and treatment, lung cancer is still an intractable disease and the second leading cause of cancer-related deaths and morbidity in the world. The family of Polo-like kinases (PLKs) consists of five serine/threonine kinases, which have been reported to participate in various human diseases. However, the expression and prognostic value of each PLK in human lung cancer have not been fully understood. This study analyzed mRNA expression and prognostic value of different PLKs in human non-small cell lung cancer (NSCLC).
METHODS
First, mRNA expression of PLKs in patients with NSCLC from the Oncomine and the Gene Expression Profiling Interactive Analysis (GEPIA) database was investigated. Then, a Kaplan-Meier plotter was employed for survival analysis. The sequence alteration for PLKs was analyzed using The Cancer Genome Atlas (TCGA) and the cBioPortal database. Additionally, we analyzed the association among different PLKs using the LinkedOmics database. Finally, the enrichment analysis of PLKs was achieved using the DAVID database.
RESULTS
The mRNA expression levels of PLK1 and PLK4 were significantly overexpressed, while mRNA expression level of PLK3 was underexpressed in patients with NSCLC. mRNA expressions of PLK1 and PLK4 were significantly and positively related to the tumor stage of NSCLC. Increased expressions of PLK1, PLK4, and PLK5 and decreased expression of PLK2 were attributed to limited overall survival time in NSCLC. PLK1 was positively correlated with PLK4 via the LinkedOmics database.
CONCLUSIONS
PLKs are relevant targets for NSCLC treatment, especially PLK1 and PLK4.
背景
尽管在早期诊断和治疗方面取得了重大进展，但肺癌仍然是一种难治性疾病，是世界上癌症相关死亡和发病率的第二大主要原因。Polo 样激酶（PLKs）家族由五种丝氨酸/苏氨酸激酶组成，据报道它们参与了各种人类疾病。然而，每种 PLK 在人类非小细胞肺癌（NSCLC）中的表达和预后价值尚未完全了解。本研究分析了不同 PLK 在人类非小细胞肺癌（NSCLC）中的 mRNA 表达和预后价值。
方法
首先，我们从 Oncomine 和基因表达谱交互式分析（GEPIA）数据库中研究了 NSCLC 患者中 PLKs 的 mRNA 表达。然后，我们使用 Kaplan-Meier 绘图器进行生存分析。使用癌症基因组图谱（TCGA）和 cBioPortal 数据库分析 PLKs 的序列改变。此外，我们使用 LinkedOmics 数据库分析不同 PLKs 之间的关联。最后，我们使用 DAVID 数据库进行 PLKs 的富集分析。
结果
PLK1 和 PLK4 的 mRNA 表达水平明显上调，而 PLK3 的 mRNA 表达水平下调。PLK1 和 PLK4 的 mRNA 表达与 NSCLC 的肿瘤分期显著正相关。PLK1、PLK4 和 PLK5 的表达增加和 PLK2 的表达减少与 NSCLC 的总生存时间有限有关。通过 LinkedOmics 数据库，PLK1 与 PLK4 呈正相关。
结论
PLKs 是 NSCLC 治疗的相关靶点，尤其是 PLK1 和 PLK4。
Zotero 插件